AstraZeneca is a British drugmaker strong in cancer, heart and respiratory medicines.
AstraZeneca PLC (AZN) is expected to report earnings on Friday, October 30, 2026, before the open. Estimated release time before open. Consensus EPS estimate is $2.60.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-27 | Jun 2026 qtr | $2.50 | $2.63 | +5.2% | $15.38B |
| 2026-04-29 | Mar 2026 qtr | $2.57 | $1.99 | — | $15.29B |
| 2026-02-24 | Dec 2025 qtr | $2.09 | $2.12 | +1.4% | $15.50B |
| 2025-11-06 | Sep 2025 qtr | $2.28 | $1.63 | — | $15.19B |
| 2025-07-29 | Jun 2025 qtr | $2.18 | $1.58 | — | $14.46B |
| 2025-03-30 | Mar 2025 qtr | $2.20 | $2.48 | — | $13.59B |
| 2024-12-31 | Dec 2024 qtr | $2.07 | $2.10 | — | $14.89B |
| 2024-09-30 | Sep 2024 qtr | $2.02 | $2.08 | — | $13.56B |
AZN has beaten consensus EPS in 2 of its last 2 scored quarters.
AZN pays a semi-annual dividend, currently yielding 2.00%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-08-07 | $1.06 | 2026-09-08 |
| 2026-02-20 | $2.17 | 2026-03-23 |
| 2025-08-08 | $0.515 | 2025-09-08 |
| 2025-02-21 | $1.05 | 2025-03-24 |
| 2024-08-09 | $0.5 | 2024-09-09 |
| 2024-02-22 | $0.985 | 2024-03-25 |